CIPROFLOXACIN HYDROCHLORIDE | N019992 | SANDOZ INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from JR Rapoza Associates, Inc. FDA-2007-P-0014 · 4 docket documents JRRapoza Associates, Inc. submitted this suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting FDA determination that Ciprofloxacin Hydrochloride Capsules in 100mg, 250mg, 500mg, and 750mg strengths are suitable for filing an Abbreviated New Drug Appli | Other | 2008-04-11 | Withdrawn | JR Rapoza Associates, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$2.91
per ml
Lowest NADAC/Unit
$0.8753
per ml
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 61314065625CIPROFLOXACIN 0.3% EYE DROP | $2.91 | ML | Generic | — | 2026-06-17 |
| 61314065605CIPROFLOXACIN 0.3% EYE DROP | $1.59 | ML | Generic | — | 2026-06-17 |
| 61314065610CIPROFLOXACIN 0.3% EYE DROP | $0.8753 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.